Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
Table 1
Patient characteristics.
Patient characteristics
Untreated (Tob−) group (mean ± SD)
Tobramycin-treated (Tob+) group (mean ± SD)
value
Age (years)
(5–21)
(9–46)
0.01
FEV1 (% predicted)
(59–131)
(27–107)
0.002
BMI (kg/m2)
(14.5–20.5)
1 (14.5–24.1)
0.036
SDS-BMI
(−2.9–0.9)
(−2.8–0.8)
ns
Liver disease
1/10 (10%)
4/46 (9%)
ns
CFRDM
0/10 (0%)
5/46 (11%)
ns
Serum creatinine (mg/dL)
ns
eCCl Schwartz (mL/min/1.73 m2)
(109–198)
(92–236)
ns
GFR 69–90 mL/min/1.73 m2
0/10 (0%)
0/46 (0%)
ns
eCCl Cockcroft-Gault (mL/min/1.73 m2)
(70–128)
(71–174)
ns
GFR 69–90 mL/min/1.73 m2
5/10 (50%)
17/46 (37%)
ns
P. aeruginosa+
0/10 (0%)
46/46 (100%)
iv tobramycin courses
0
(1–57)
Results are presented as mean ± SD (range). Untreated (Tob−) group: CF patients that never received intravenous AG antibiotics, Tobramycin-treated (Tob+) group: CF patients that received various courses of intravenous tobramycin antibiotics.
